GSK (GSK)

Sector:

Pharma and Biotech

Index:

FTSE 100

2,181.00p
   
  • Change Today:
    -33.00p
  • 52 Week High: 2,268.00p
  • 52 Week Low: 1,264.00p
  • Currency: UK Pounds
  • Shares Issued: 4,073.10m
  • Volume: 1,590,730
  • Market Cap: £88,834m
  • RiskGrade: 129
  • Beta: 0.78

GSK Overview

We are a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together. We aim to positively impact the health of 2.5 billion people by the end of 2030. Our bold ambitions for patients are reflected in commitments to growth and a step-change in performance. We are a company where outstanding people can thrive.

1 Day Chart

1 Day Chart

6 Month Chart

6 Month Chart
Barclays logo

Digital Look Charts Sponsored by Barclays Stockbrokers

Financials

Latest F'cast
Div Yield 3.0% 0.0%
Div Cover 2.6 2.6
Op Mrgn 24.3% 28.8%
ROCE 73.4%  
Latest F'cast
P/E 12.9 12.2
PEG 1.6 2.2
Pr/Revenue 2.8 2.7
Pr/Book 5.7  
Latest F'cast
Revenue 4.1% 3.6%
PBT 112.9% 31.9%
EPS 8.0% 5.5%
DPS 8.2% 6.8%

GSK Fundamentals

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-21 24,696.00 3,599.00 90.56p 22.2 n/a -22% 80.00p 4.0%
31-Dec-22 29,324.00 5,628.00 139.70p 10.3 0.2 +54% 44.00p 3.1%
31-Dec-23 30,328.00 6,064.00 155.10p 9.4 0.9 +11% 58.00p 4.0%
31-Dec-24 31,376.00 3,477.00 159.30p 8.5 2.8 +3% 61.00p 4.5%
31-Dec-25 32,667.00 7,401.00 172.00p 10.6 1.3 +8% 66.00p 3.6%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

GSK Forecasts

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-26 33,848.41 9,763.76 181.46p 12.2 2.2 +6% 70.49p 0.0%
31-Dec-27 35,517.27 10,468.76 196.57p 11.3 1.4 +8% 74.80p 0.0%
31-Dec-28 36,611.60 10,790.99 204.88p 10.8 2.6 +4% 79.71p 0.0%

Copyright © 2026 FactSet Research Systems Inc. All rights reserved.

GSK Company Announcements

Linerixibat accepted for priority review in China 26-Feb-2026 07:05 RNS
Bepirovirsen accepted for Japan regulatory review 26-Feb-2026 07:00 RNS
Transaction in Own Shares 26-Feb-2026 07:00 RNS

GSK ShareCast News

GSK secures Japan and China reviews for two late... 26-Feb-2026 ShareCast
GSK to acquire Canada's 35Pharma for $950m 25-Feb-2026 ShareCast
GSK's Exdensur gets green light from European Co... 17-Feb-2026 ShareCast

GSK Top Newspaper Links

GlaxoSmithKline scraps sale of old drugs 05-Dec-2014 Telegraph
Glaxo sharpens axe to save £1bn as insurers and ... 01-Dec-2014 The Independent
GSK to cut hundreds of US jobs 01-Dec-2014 Telegraph

Latest GSK Director Deals

Traded Action Notifier PriceAmountValue
20-Feb-26 Buy Hal Barron 4,415.59p 64 £2,825.98
20-Feb-26 Buy Dividends Hal Barron 4,415.59p 2,007,552 £88,645,348.67
20-Feb-26 Buy Wendy Becker 2,219.26p 3,334 £73,990.13

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

 

GSK Market Data

Currency UK Pounds
Share Price 2,181.00p
Change Today -33.00p
% Change -1.49 %
52 Week High 2,268.00p
52 Week Low 1,264.00p
Volume 1,590,730
Shares Issued 4,073.10m
Market Cap £88,834m
Beta 0.78
RiskGrade 129

GSK Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value Not Available
Price Trend
6.98% above the market average6.98% above the market average6.98% above the market average6.98% above the market average6.98% above the market average
36.36% above the sector average36.36% above the sector average36.36% above the sector average36.36% above the sector average36.36% above the sector average
Income Not Available
Growth Not Available

What The Brokers Say

Strong Buy 4
Buy 3
Neutral 13
Sell 3
Strong Sell 0
Total 23
neutral
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

GSK Dividends

  Latest Previous
  Q4 Q3
Ex-Div 19-Feb-26 13-Nov-25
Paid 09-Apr-26 08-Jan-26
Amount 18.00p 16.00p

Trades for 26-Feb-2026

Time Volume / Share Price
13:29 0 @ 2,180.00p
13:29 0 @ 2,181.00p
13:29 10 @ 2,181.00p
13:28 136 @ 2,181.00p
13:28 5 @ 2,181.00p

GSK Key Personnel

CEO Luke Miels

Top of Page